New Evidence Supports Use of Weight-Loss Medication for Schizophrenia Patients

A groundbreaking study shows that semaglutide, a diabetic weight-loss drug, is safe and effective for reducing obesity in people with schizophrenia without worsening psychiatric symptoms. This promotes better health outcomes for this high-risk group.
Recent research conducted by the University of Queensland has demonstrated that certain diabetic weight-loss medications are both effective and safe for individuals with schizophrenia, without exacerbating their psychiatric symptoms. In a 36-week clinical trial, the medication semaglutide—commonly found in drugs like Ozempic and Wegovy—was shown to significantly aid weight loss among patients, a crucial development given the high risk of obesity-related complications in this population.
Patients with schizophrenia often experience weight gain due to antipsychotic medications, such as clozapine, which many find difficult to tolerate long-term. This weight gain can lead to a substantial reduction in life expectancy, with the gap to the general population's lifespan extending to approximately 16 years. The trial revealed that participants taking semaglutide lost nearly 14% of their body weight, compared to those on a placebo, suggesting strong therapeutic potential.
Importantly, the study found that semaglutide did not interfere with mental health, psychotic symptoms, or the levels of antipsychotic drugs. It also improved the ratio of lean to fat mass, indicating more effective fat loss. These findings are particularly notable because they were obtained without pharmaceutical company involvement, adding to their credibility.
Currently, in Australia, semaglutide is not included in the Pharmaceutical Benefits Scheme (PBS) for weight management, underscoring the need for wider access due to the urgent health disparities faced by people with schizophrenia. Experts advocate for policy changes to improve affordability and availability, enabling this vulnerable group to benefit from such effective treatment options.
This pioneering research, published in The Lancet Psychiatry, offers a promising avenue for improving physical health outcomes in individuals with schizophrenia, supporting both weight management and overall well-being.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
New Insights into Iron-Induced Cell Death and Its Role in Inflammatory Bowel Disease
New research reveals how iron-dependent cell death, specifically ferroptosis, contributes to inflammatory bowel disease, opening up novel therapeutic possibilities targeting this pathway.
First Measles Case of 2025 Reported in South Carolina
A new case of measles has been confirmed in South Carolina, emphasizing the importance of vaccination and ongoing public health efforts to prevent outbreaks in 2025. Learn more about this development and its implications.
Rising Mortality from Unintentional Falls Among Older Adults in the U.S.
Older Americans are experiencing a rising rate of fatalities due to unintentional falls, highlighting a critical public health concern for the aging population. Learn more about the trends, disparities, and prevention strategies.